Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bioinvent Ab (BOVNF)

Bioinvent Ab (BOVNF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance

Most Recent Stories

More News
BioInvent's BI-1206 could improve treatment in several cancers

BOVNF : 0.1847 (unch)
BioInvent Enrolls First Patient in Phase I/IIa Trial of BI-1206 in Combination With KEYTRUDA� for the Treatment of Patients With Solid Tumors

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today...

BOVNF : 0.1847 (unch)
BioInvent Presents Proof-of-concept Data for two TNFR2-targeting Antibodies

, /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer...

BOVNF : 0.1847 (unch)
Transgene's and BioInvent's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models

Regulatory News:

BOVNF : 0.1847 (unch)
Proposal for a New Board Member to be Elected at the Extraordinary General Meeting on July 3, 2020

, /PRNewswire/ -- (OMXS: BINV)  

BOVNF : 0.1847 (unch)
HBMBF : 324.0000 (+14.75%)
BioInvent and Transgene Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors

and , /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer...

BOVNF : 0.1847 (unch)
BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development

, /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV) today announces the presentation of promising new data on its anti-tumor necrosis factor receptor 2 (TNFR2) program at the American...

BOVNF : 0.1847 (unch)
BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development

LUND, Sweden , May 15, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV) today announces the presentation of promising new data on its anti-tumor necrosis factor receptor...

BOVNF : 0.1847 (unch)
Transgene and BioInvent Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors

Regulatory News:

BOVNF : 0.1847 (unch)
BioInvent Signs New Manufacturing Agreement With U.S. Cell Therapy Company

, /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer...

BOVNF : 0.1847 (unch)
Trade BOVNF with:

Key Turning Points

2nd Resistance Point N/A
1st Resistance Point N/A
Last Price 0.1847
1st Support Level N/A
2nd Support Level N/A

See More

52-Week High 0.1847
Fibonacci 61.8% 0.1847
Fibonacci 50% 0.1847
Fibonacci 38.2% 0.1847
Last Price 0.1847
52-Week Low 0.1847

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar